2-(4-(benzyloxy)-3-nitrophenyl)acetonitrile

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-(benzyloxy)-3-nitrophenyl)acetonitrile
• 英文别名: (4-Benzyloxy-3-nitrophenyl)acetonitrile；2-(3-nitro-4-phenylmethoxyphenyl)acetonitrile
• 化学式: C₁₅H₁₂N₂O₃
• 分子量: 268.272
• InChiKey: NZYBPPHFWOWHIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  78.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(4-(benzyloxy)-3-nitrophenyl)acetonitrile 在 吡啶 、 5%-palladium/activated carbon 、 氢气 、 sodium hydride 作用下， 以 甲醇 、 二氯甲烷 、 二甲基亚砜 、 mineral oil 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 32.0h， 生成 5-bromo-N-(5-(1-cyanocyclohexyl)-2-hydroxyphenyl)-2-hydroxybenzenesulfonamide
  参考文献：
  名称：

  Discovery and Optimization of Salicylic Acid-Derived Sulfonamide Inhibitors of the WD Repeat-Containing Protein 5–MYC Protein–Protein Interaction

  摘要：

  The treatment of tumors driven by overexpression or amplification of MYC oncogenes remains a significant challenge in drug discovery. Here, we present a new strategy toward the inhibition of MYC via the disruption of the protein-protein interaction between MYC and its chromatin cofactor WD Repeat-Containing Protein 5. Blocking the association of these proteins is hypothesized to disrupt the localization of MYC to chromatin, thus disrupting the ability of MYC to sustain tumorigenesis. Utilizing a high-throughput screening campaign and subsequent structure-guided design, we identify small-molecule inhibitors of this interaction with potent in vitro binding affinity and report structurally related negative controls that can be used to study the effect of this disruption. Our work suggests that disruption of this protein-protein interaction may provide a path toward an effective approach for the treatment of multiple tumors and anticipate that the molecules disclosed can be used as starting points for future efforts toward compounds with improved drug-like properties.

  DOI：

  10.1021/acs.jmedchem.9b01411
• 作为产物：
  描述：

  对羟基苯乙腈 在 硫酸 、 硝酸 、 potassium carbonate 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 18.0h， 生成 2-(4-(benzyloxy)-3-nitrophenyl)acetonitrile
  参考文献：
  名称：

  Discovery and Optimization of Salicylic Acid-Derived Sulfonamide Inhibitors of the WD Repeat-Containing Protein 5–MYC Protein–Protein Interaction

  摘要：

  The treatment of tumors driven by overexpression or amplification of MYC oncogenes remains a significant challenge in drug discovery. Here, we present a new strategy toward the inhibition of MYC via the disruption of the protein-protein interaction between MYC and its chromatin cofactor WD Repeat-Containing Protein 5. Blocking the association of these proteins is hypothesized to disrupt the localization of MYC to chromatin, thus disrupting the ability of MYC to sustain tumorigenesis. Utilizing a high-throughput screening campaign and subsequent structure-guided design, we identify small-molecule inhibitors of this interaction with potent in vitro binding affinity and report structurally related negative controls that can be used to study the effect of this disruption. Our work suggests that disruption of this protein-protein interaction may provide a path toward an effective approach for the treatment of multiple tumors and anticipate that the molecules disclosed can be used as starting points for future efforts toward compounds with improved drug-like properties.

  DOI：

  10.1021/acs.jmedchem.9b01411

文献信息

• [EN] WDR5-MYC INHIBITORS<br/>[FR] INHIBITEURS DE WDR5-MYC
  申请人：UNIV VANDERBILT

  公开号：WO2021021951A1

  公开（公告）日：2021-02-04

  Substituted N-phenyl sulfonamide compounds inhibit WDR5-MYC interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject, such as cancer cell proliferation.

  取代的N-苯基磺酰胺化合物可以抑制WDR5-MYC相互作用，这些化合物及其药物组合物可用于治疗受试者中的疾病和状况，如癌细胞增殖。
• Novel dopamine derivatives, processes for their preparation, and their
  申请人：Schering Aktiengesllschaft

  公开号：US04958026A1

  公开（公告）日：1990-09-18

  The disclosure relates to novel dopamine derivatives of general Formula I ##STR1## wherein A is a substituted phenyl residue of the structure ##STR2## wherein R.sup.1 and R.sup.2, being identical or different, mean hydrogen, C.sub.1-15 -alkyl and allyl, D is ##STR3## R.sub.4 is hydrogen, C.sub.1 -C.sub.4 -alkyl, CF.sub.3, NH.sub.2 E is ##STR4## X is OH, NH.sub.2, ##STR5## and NH--SO.sub.2 --CF.sub.3, if Y=OH, Y is OH, NH.sub.2, ##STR6## NH--SO.sub.2 --CF.sub.3 and NH--SO.sub.2 --CH.sub.3, if X=OH, but wherein X and Y do not simultaneously mean OH, with R.sup.3 being C.sub.1-4 -alkyl, and Z is H or OH, and, if Z means the hydroxy group, the residue A can also be present in the tautomeric basic form, and their acid addition salts, their preparation, and use as medicinal agents having antihypertensive activity.

  本公开涉及一种新型多巴胺衍生物，其一般式为I ##STR1## 其中A是结构为##STR2##的取代苯基残基，其中R.sup.1和R.sup.2相同或不同，表示氢、C.sub.1-15-烷基和丙烯基，D是##STR3## R.sub.4是氢、C.sub.1-C.sub.4-烷基、CF.sub.3、NH.sub.2，E是##STR4## X是OH、NH.sub.2、##STR5##和NH--SO.sub.2--CF.sub.3，如果Y=OH，则Y是OH、NH.sub.2、##STR6## NH--SO.sub.2--CF.sub.3和NH--SO.sub.2--CH.sub.3，如果X=OH，则X和Y不能同时表示OH，其中R.sup.3是C.sub.1-4-烷基，Z是H或OH，如果Z表示羟基，则残基A也可以以互变异构体的碱性形式存在，以及它们的酸加成盐、制备方法和用作具有降压活性的药物。
• ——
  作者：ALBRECHT R.、 LEHMANN M.、 SCHRODER G.

  DOI：——

  日期：——
• NEUE DOPAMIN-DERIVATE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG ALS ARZNEIMITTEL
  申请人：SCHERING AKTIENGESELLSCHAFT

  公开号：EP0189473A1

  公开（公告）日：1986-08-06
• US4958026A
  申请人：——

  公开号：US4958026A

  公开（公告）日：1990-09-18